DH DIAGNOSTICS, LLC

View full entity profile (contributions, contracts, SEC) →

This entity appears on both sides of lobbying disclosures. The firm tab shows registrant-reported income; the client tab shows client-reported lobbying spend. Contract awards are separate and are not included here.

Lobbying Spend

$1.8M

Filings

Firms Hired

Active Period

2024–2026

Lobbying Spend by Year

Client-reported lobbying expenses on LDA filings

Year	Lobbying Spend	Filings	Firms
2026	$780,000	8	3
2025	$736,000	12	3
2024	$240,000	10	3

Hired Firms

Lobbying firms retained by this client; amounts are client-reported expenses when available

Firm Name	Reported Spend	Filings
DH DIAGNOSTICS, LLC	$1,756,000	10
TIBER CREEK GROUP	—	10
TODD STRATEGY GROUP	—	10

Government Bodies Lobbied

Government entities explicitly identified as targets in LDA filings

Government Body	Filings
HOUSE OF REPRESENTATIVES	27
SENATE	26
Health & Human Services, Dept of (HHS)	11
Defense, Dept of (DOD)	3
Veterans Affairs, Dept of (VA)	3
Food & Drug Administration (FDA)	2
State, Dept of (DOS)	2
White House Office	2
Commerce, Dept of (DOC)	1

Top Issues

Most frequently reported lobbying issues

Issue Code	Description	Reports
Health Issues	Health Issues	30
Medicare/Medicaid	Medicare/Medicaid	17
Budget/Appropriations	Budget/Appropriations	6
Tariff (miscellaneous tariff bills)	Tariff (miscellaneous tariff bills)	3
Trade (domestic/foreign)	Trade (domestic/foreign)	3

Bills Explicitly Cited (25)

Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded

H.R. 5269119th Congress

RESULTS Act

2026 · third_quarter · Firm: DH DIAGNOSTICS, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to diagnostic testing, Oncology and the Reforming and Enhancing Sustainable Updates to Laboratory Services (the RESULTS Act, S.2761/H.R. 5269). S.1399/H.R.6197, the Health Tech Investment Act S.3287/H.R.6130, Alzheimer's Screening and Prevention (ASAP) Act

Client expense: $310,000 · Firm income: —

Matched citations: H.R. 5269

H.R. 6130119th Congress

ASAP Act

2026 · third_quarter · Firm: DH DIAGNOSTICS, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to diagnostic testing, Oncology and the Reforming and Enhancing Sustainable Updates to Laboratory Services (the RESULTS Act, S.2761/H.R. 5269). S.1399/H.R.6197, the Health Tech Investment Act S.3287/H.R.6130, Alzheimer's Screening and Prevention (ASAP) Act

Client expense: $310,000 · Firm income: —

Matched citations: H.R.6130

H.R. 6197119th Congress

Health Tech Investment Act

2026 · third_quarter · Firm: DH DIAGNOSTICS, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to diagnostic testing, Oncology and the Reforming and Enhancing Sustainable Updates to Laboratory Services (the RESULTS Act, S.2761/H.R. 5269). S.1399/H.R.6197, the Health Tech Investment Act S.3287/H.R.6130, Alzheimer's Screening and Prevention (ASAP) Act

Client expense: $310,000 · Firm income: —

Matched citations: H.R.6197

H.R. 7352119th Congress

PASTEUR Act of 2026

2026 · third_quarter · Firm: DH DIAGNOSTICS, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to diagnostic testing, Oncology, Hepatitis C funding H.R.7352/S.4875, the Pioneering Antimicrobial Subscriptions To End Upsurging Resistence Act of 2026 (PASTEUR Act) S.1941, the Cure Hepatitis C Act of 2025

Client expense: $310,000 · Firm income: —

Matched citations: H.R.7352

Show 21 more cited filings

S. 1399119th Congress

Health Tech Investment Act

2026 · third_quarter · Firm: DH DIAGNOSTICS, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to diagnostic testing, Oncology and the Reforming and Enhancing Sustainable Updates to Laboratory Services (the RESULTS Act, S.2761/H.R. 5269). S.1399/H.R.6197, the Health Tech Investment Act S.3287/H.R.6130, Alzheimer's Screening and Prevention (ASAP) Act

Client expense: $310,000 · Firm income: —

Matched citations: S.1399

S. 1941119th Congress

Cure Hepatitis C Act of 2025

2026 · third_quarter · Firm: DH DIAGNOSTICS, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to diagnostic testing, Oncology, Hepatitis C funding H.R.7352/S.4875, the Pioneering Antimicrobial Subscriptions To End Upsurging Resistence Act of 2026 (PASTEUR Act) S.1941, the Cure Hepatitis C Act of 2025

Client expense: $310,000 · Firm income: —

Matched citations: S.1941

S. 2761119th Congress

RESULTS Act

2026 · third_quarter · Firm: DH DIAGNOSTICS, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to diagnostic testing, Oncology and the Reforming and Enhancing Sustainable Updates to Laboratory Services (the RESULTS Act, S.2761/H.R. 5269). S.1399/H.R.6197, the Health Tech Investment Act S.3287/H.R.6130, Alzheimer's Screening and Prevention (ASAP) Act

Client expense: $310,000 · Firm income: —

Matched citations: S.2761

S. 3287119th Congress

Fair Allocation of Interstate Rates Act

2026 · third_quarter · Firm: DH DIAGNOSTICS, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to diagnostic testing, Oncology and the Reforming and Enhancing Sustainable Updates to Laboratory Services (the RESULTS Act, S.2761/H.R. 5269). S.1399/H.R.6197, the Health Tech Investment Act S.3287/H.R.6130, Alzheimer's Screening and Prevention (ASAP) Act

Client expense: $310,000 · Firm income: —

Matched citations: S.3287

S. 4875119th Congress

PASTEUR Act of 2026

2026 · third_quarter · Firm: DH DIAGNOSTICS, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to diagnostic testing, Oncology, Hepatitis C funding H.R.7352/S.4875, the Pioneering Antimicrobial Subscriptions To End Upsurging Resistence Act of 2026 (PASTEUR Act) S.1941, the Cure Hepatitis C Act of 2025

Client expense: $310,000 · Firm income: —

Matched citations: S.4875

H.R. 5269119th Congress

RESULTS Act

2026 · third_quarter · Firm: TIBER CREEK GROUP

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to reimbursement for diagnostic tests; Issues related to H.R. 5269/S. 2761 - RESULTS Act; Issues related to H.R. 7352/S. 4875 - PASTEUR Act of 2026; Issues related to H.R. 6197/S. 1399 - Health Tech Investment Act; Issues related to H.R. 6130/S. 3267 - ASAP Act.

Client expense: — · Firm income: $70,000

Matched citations: H.R. 5269

H.R. 6130119th Congress

ASAP Act

2026 · third_quarter · Firm: TIBER CREEK GROUP

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to reimbursement for diagnostic tests; Issues related to H.R. 5269/S. 2761 - RESULTS Act; Issues related to H.R. 7352/S. 4875 - PASTEUR Act of 2026; Issues related to H.R. 6197/S. 1399 - Health Tech Investment Act; Issues related to H.R. 6130/S. 3267 - ASAP Act.

Client expense: — · Firm income: $70,000

Matched citations: H.R. 6130

H.R. 6197119th Congress

Health Tech Investment Act

2026 · third_quarter · Firm: TIBER CREEK GROUP

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to reimbursement for diagnostic tests; Issues related to H.R. 5269/S. 2761 - RESULTS Act; Issues related to H.R. 7352/S. 4875 - PASTEUR Act of 2026; Issues related to H.R. 6197/S. 1399 - Health Tech Investment Act; Issues related to H.R. 6130/S. 3267 - ASAP Act.

Client expense: — · Firm income: $70,000

Matched citations: H.R. 6197

H.R. 7352119th Congress

PASTEUR Act of 2026

2026 · third_quarter · Firm: TIBER CREEK GROUP

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to reimbursement for diagnostic tests; Issues related to H.R. 5269/S. 2761 - RESULTS Act; Issues related to H.R. 7352/S. 4875 - PASTEUR Act of 2026; Issues related to H.R. 6197/S. 1399 - Health Tech Investment Act; Issues related to H.R. 6130/S. 3267 - ASAP Act.

Client expense: — · Firm income: $70,000

Matched citations: H.R. 7352

H.R. 7352119th Congress

PASTEUR Act of 2026

2026 · third_quarter · Firm: TIBER CREEK GROUP

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to point of care testing and digital pathology; Issues related to H.R. 7352/S. 4875 - PASTEUR Act of 2026; Issues related to infectious disease diagnostics.

Client expense: — · Firm income: $70,000

Matched citations: H.R. 7352

S. 1399119th Congress

Health Tech Investment Act

2026 · third_quarter · Firm: TIBER CREEK GROUP

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to reimbursement for diagnostic tests; Issues related to H.R. 5269/S. 2761 - RESULTS Act; Issues related to H.R. 7352/S. 4875 - PASTEUR Act of 2026; Issues related to H.R. 6197/S. 1399 - Health Tech Investment Act; Issues related to H.R. 6130/S. 3267 - ASAP Act.

Client expense: — · Firm income: $70,000

Matched citations: S. 1399

S. 2761119th Congress

RESULTS Act

2026 · third_quarter · Firm: TIBER CREEK GROUP

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to reimbursement for diagnostic tests; Issues related to H.R. 5269/S. 2761 - RESULTS Act; Issues related to H.R. 7352/S. 4875 - PASTEUR Act of 2026; Issues related to H.R. 6197/S. 1399 - Health Tech Investment Act; Issues related to H.R. 6130/S. 3267 - ASAP Act.

Client expense: — · Firm income: $70,000

Matched citations: S. 2761

S. 3267119th Congress

ASAP Act

2026 · third_quarter · Firm: TIBER CREEK GROUP

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to reimbursement for diagnostic tests; Issues related to H.R. 5269/S. 2761 - RESULTS Act; Issues related to H.R. 7352/S. 4875 - PASTEUR Act of 2026; Issues related to H.R. 6197/S. 1399 - Health Tech Investment Act; Issues related to H.R. 6130/S. 3267 - ASAP Act.

Client expense: — · Firm income: $70,000

Matched citations: S. 3267

S. 4875119th Congress

PASTEUR Act of 2026

2026 · third_quarter · Firm: TIBER CREEK GROUP

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to reimbursement for diagnostic tests; Issues related to H.R. 5269/S. 2761 - RESULTS Act; Issues related to H.R. 7352/S. 4875 - PASTEUR Act of 2026; Issues related to H.R. 6197/S. 1399 - Health Tech Investment Act; Issues related to H.R. 6130/S. 3267 - ASAP Act.

Client expense: — · Firm income: $70,000

Matched citations: S. 4875

S. 4875119th Congress

PASTEUR Act of 2026

2026 · third_quarter · Firm: TIBER CREEK GROUP

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to point of care testing and digital pathology; Issues related to H.R. 7352/S. 4875 - PASTEUR Act of 2026; Issues related to infectious disease diagnostics.

Client expense: — · Firm income: $70,000

Matched citations: S. 4875

H.R. 5269119th Congress

RESULTS Act

2026 · second_quarter · Firm: DH DIAGNOSTICS, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to diagnostic testing, Oncology and the Reforming and Enhancing Sustainable Updates to Laboratory Services (the RESULTS Act, S.2761/H.R. 5269). S.1399/H.R.6197, the Health Tech Investment Act S.3287/H.R.6130, Alzheimer's Screening and Prevention (ASAP) Act

Client expense: $220,000 · Firm income: —

Matched citations: H.R. 5269

H.R. 6130119th Congress

ASAP Act

2026 · second_quarter · Firm: DH DIAGNOSTICS, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to diagnostic testing, Oncology and the Reforming and Enhancing Sustainable Updates to Laboratory Services (the RESULTS Act, S.2761/H.R. 5269). S.1399/H.R.6197, the Health Tech Investment Act S.3287/H.R.6130, Alzheimer's Screening and Prevention (ASAP) Act

Client expense: $220,000 · Firm income: —

Matched citations: H.R.6130

H.R. 6197119th Congress

Health Tech Investment Act

2026 · second_quarter · Firm: DH DIAGNOSTICS, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to diagnostic testing, Oncology and the Reforming and Enhancing Sustainable Updates to Laboratory Services (the RESULTS Act, S.2761/H.R. 5269). S.1399/H.R.6197, the Health Tech Investment Act S.3287/H.R.6130, Alzheimer's Screening and Prevention (ASAP) Act

Client expense: $220,000 · Firm income: —

Matched citations: H.R.6197

H.R. 7352119th Congress

PASTEUR Act of 2026

2026 · second_quarter · Firm: DH DIAGNOSTICS, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to diagnostic testing, Oncology, Hepatitis C funding H.R.7352/S.4875, the Pioneering Antimicrobial Subscriptions To End Upsurging Resistence Act of 2026 (PASTEUR Act) S.1941, the Cure Hepatitis C Act of 2025

Client expense: $220,000 · Firm income: —

Matched citations: H.R.7352

S. 1399119th Congress

Health Tech Investment Act

2026 · second_quarter · Firm: DH DIAGNOSTICS, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to diagnostic testing, Oncology and the Reforming and Enhancing Sustainable Updates to Laboratory Services (the RESULTS Act, S.2761/H.R. 5269). S.1399/H.R.6197, the Health Tech Investment Act S.3287/H.R.6130, Alzheimer's Screening and Prevention (ASAP) Act

Client expense: $220,000 · Firm income: —

Matched citations: S.1399

S. 1941119th Congress

Cure Hepatitis C Act of 2025

2026 · second_quarter · Firm: DH DIAGNOSTICS, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to diagnostic testing, Oncology, Hepatitis C funding H.R.7352/S.4875, the Pioneering Antimicrobial Subscriptions To End Upsurging Resistence Act of 2026 (PASTEUR Act) S.1941, the Cure Hepatitis C Act of 2025

Client expense: $220,000 · Firm income: —

Matched citations: S.1941

Source: Senate LDA

DH DIAGNOSTICS, LLC — Lobbying Disclosure | Poliscope